CelLBxHealth plc
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Peter Collins
- Full Time Employees
- 119
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Address
- Surrey Research Park Guildford United Kingdom GU2 7AF
- IPO Date
- Apr 28, 2015
- Website
- cellbxhealth.com
- Similar Companies
- Business
- CelLBxHealth plc, a medical diagnostics innovator, delivers advanced cancer diagnostic solutions across the United Kingdom, Europe, North America, and other global regions. The company's core offering centers on its proprietary Parsortix platform. This includes the Parsortix PC1 system, an FDA-cleared medical device designed for the isolation and retrieval of intact circulating tumor cells (CTCs) from the blood of metastatic breast cancer patients, facilitating subsequent user-validated analysis. Additionally, the Parsortix PR1 system is available for research applications, enabling the capture and harvest of CTCs from blood samples. Supporting its platforms, CelLBxHealth provides the Portrait+ CTC Staining kit, a laboratory solution offering analytical sensitivity and specificity for identifying, characterizing, and counting epithelial and mesenchymal CTCs. The CellKeep Slide further enhances the workflow, acting as a CTC harvesting technology compatible with automated immunohistochemistry (IHC) systems, as recently demonstrated in a proof-of-concept study with Roche Tissue Diagnostics' BenchMark ULTRA automated workflow. Beyond its product suite, the company offers specialized laboratory services through its GCLP-certified UK facility, encompassing CTC enrichment, comprehensive liquid biopsy analysis, clinical trial support, and tailored assay development. Their assay portfolio features Portrait Flex for immunofluorescence analysis of epithelial and mesenchymal transition, DNA damage response evaluation, Portrait PD-L1 for CTC assessment, and custom CTC assays. CelLBxHealth is actively engaged in strategic collaborations, including a recent co-marketing agreement with QIAGEN to promote the Parsortix system to pharmaceutical partners, aiming to integrate CTC enrichment with molecular analysis technologies for drug development, biomarker discovery, and companion diagnostic feasibility. Further partnerships include BioView Ltd for a human epidermal growth factor receptor 2 (HER2) assay kit in breast cancer and NuProbe USA, Inc. for pan-cancer next-generation sequencing (NGS) panels, and a collaboration with Myriad Genetics Inc. for cancer patient sample analysis. An international expert consensus recently recognized the Parsortix platform as a leading next-generation technology for CTC analysis, highlighting its clinical relevance in cancer management. Formerly known as ANGLE plc, the company rebranded to CelLBxHealth plc in October 2025, reflecting its sharpened focus on circulating tumor cell intelligence. Established in 1994, CelLBxHealth plc is headquartered in Guildford, United Kingdom.
CelLBxHealth shares rise 8% on Royal Marsden lung cancer collaboration
CelLBxHealth joins forces with The Royal Marsden on lung cancer liquid biopsy study
CelLBxHealth shares rise 3% as company continues to focus on cost base
CelLBxHealth drops FDA device listing to cut costs and refocus on revenue growth
CelLBxHealth backed for rebound by broker
CelLBxHealth enters 2026 with strong pipeline
CelLBxHealth Health confirms boardroom appointments
T. ROWE PRICE LAUNCHES SEASON 5 OF "THE ANGLE" PODCAST SERIES WITH EXPLORATION OF THE GLOBAL ENERGY SECTOR
ANGLE plc (OTCMKTS:ANPCY) Short Interest Down 94.5% in December
CellbxHealth raises just shy of £1m in retail offer
CelLBxHealth plc (ANPCY) Discusses New Strategy and Business Plan Focused on Commercialization and Liquid Biopsy Innovation Transcript
CelLBxHealth plans £6.8 million fundraise as it pushes for commercial reboot
CelLBxHealth PLC Presents Proof-of-Concept Study
CelLBxHealth backed by expert panel as Parsortix named top cancer technology and plans £6m fundraise
Cellbxhealth PLC Announces Expert Consensus on CTCs; Update on Funding
ANGLE appoints interim CEO ahead of name change and restructure
ANGLE plc Announces Appointments: Interim CEO and Senior Board Advisor
ANGLE to rebrand as CelLBxHealth and shift focus under new executive chairman
Angle PLC Announces Strategy Update
ANGLE 'delighted' as it reveals new clinical data